Alzheimer's disease
Neurology · 2007–2015
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| rivastigmine Treatment of mild to moderately severe Alzheimer-type dementia. The 13.3 milligrams/24 hours patch strength provides an additional dosing option for patients… | Jul 2015 | Recommended | none received |
| memantine hydrochloride Treatment of moderately severe Alzheimer's disease in patients with baseline (Standardised) Mini-Mental State Examination (SMMSE) score of 10-14. | Mar 2008 | Recommended with restriction | no section in document |
| memantine hydrochloride Treatment of moderately severe Alzheimer's disease in patients with a baseline Mini-Mental State Examination (MMSE) score of 10-14. | Mar 2007 | Not recommended | no section in document |
| memantine hydrochloride Treatment of moderately severe Alzheimer's disease in patients with baseline Mini-Mental State Examination score of 10-14. | Mar 2007 | Not recommended | no section in document |
What the PBS pays
$12M in government benefit over 2024–25, across 224,872 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| rivastigmine | $7.1M |
| memantine hydrochloride | $4.4M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| donepezil galantamine rivastigmine and memantineDonepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | TA217 | recommended | 2011-03 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| donepezilAPO-DONEPEZIL donepezil hydrochloride (as monohydrate) 10 mg tablet bl | 1998 | 52 |
| galantamineAPO-GALANTAMINE MR galantamine (as hydrobromide) 16 mg modified releas | 2010 | 22 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.